science wire

« BACK

Pharmacology



Results 551 - 600 of 1511.
« Previous 1 ... 8 9 10 11 12 13 14 15 16 ... 31 Next »


Pharmacology - Health - 06.02.2018
Phase III IMmotion151 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer
Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cance

Health - Pharmacology - 31.01.2018
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL Analysis of 75 patients with m

Pharmacology - Health - 26.01.2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) † Advanced Accelerator Applications is a newly established subsidiary of Novartis † Lutathera expands Novartis' n

Health - Pharmacology - 26.01.2018

Pharmacology - Health - 26.01.2018
CHMP recommends EU approval of Roche’s Hemlibra for people with haemophilia A with inhibitors
Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents in two phase III studies across age groups With once-weekly subcutaneous (under the skin) administration, Hem

Pharmacology - Business / Economics - 24.01.2018
Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase
Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto , more than offset Gleevec/Glivec generic erosion: Cosentyx grew to USD 2.1 bi

Health - Pharmacology - 24.01.2018
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss
Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss Novartis enters into a licensing and supply agre

Pharmacology - Health - 22.01.2018
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments LIBERTY is the first mi

Health - Pharmacology - 17.01.2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL
Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy † EMA granted accelerate

Health - Pharmacology - 16.01.2018
Novartis new data reinforces superiority of Cosentyx versus Stelara * in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx (secukinumab) was significantly more effective than Stelara * (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks Data support findings from the CLEAR study, which found Cosentyx was superior to Stelara * in achieving sustained skin clearance (PASI 90) at 52 weeks Cosentyx is the first and only fully human interleukin-17A (IL-17A) inhibitor that showed sustained skin cleara

Business / Economics - Pharmacology - 11.01.2018

Pharmacology - Health - 09.01.2018
Novartis advances head-to-head superiority trials of Cosentyx versus Humira * and proposed biosimilar adalimumab**
SURPASS is the first†head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis†(AS) EXCEED is the first†head-to-head superiority trial versus Humira * in†psoria

Health - Pharmacology - 04.01.2018
Roche launches the cobas Plasma Separation Card to increase access to HIV testing for patients living in remote areas
New technology allows better testing and monitoring of HIV patients living in remote settings For the first time, patient plasma samples no longer need refrigeration during transport to the lab Card

Health - Pharmacology - 04.01.2018
Novartis drug Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Data supporting designation showed over half of treatment-naÔve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of

Pharmacology - Health - 03.01.2018
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis Kisqali received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in preor perimenopausal women who received no prior endocrine therapy for advanced disease Treatment benefit with K

Pharmacology - Health - 22.12.2017
Novartis’ combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I

Pharmacology - Health - 22.12.2017
Novartis drug Tasigna is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
Inclusion of Treatment-free Remission (TFR) data provides additional and novel option in management of Ph+ CML-CP † Deep and sustained molecular response included as key eligibility criteria for atte

Pharmacology - Health - 21.12.2017
European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer
European Commission approves Roche's Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer Alecensa provides a new treatment option for people with newly diagnosed ALK-positive NSC

Pharmacology - Health - 13.12.2017
Look up to the stars
A trial designed and co-ordinated by the University of Birmingham's Cancer Research UK Clinical Trials Unit to test an experimental drug in patients with head and neck cancer has launched today through the Combinations Alliance - a joint initiative between Cancer Research UK and the Experimental Cancer Medicine Centres (ECMC) Network.

Pharmacology - Health - 12.12.2017
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated c

Health - Pharmacology - 11.12.2017
Using 3D cell cultures to fight anti-cancer therapy resistance
Using 3D cell cultures to fight anti-cancer therapy resistance
An international research team headed by the University of Bern and the Netherlands Cancer Institute has developed 3D cell cultures in which genes can be specifically modified. They allow the study of genes that may cause therapy resistance in breast cancer. This knowledge may further improve the use of targeted anti-cancer drugs.

Health - Pharmacology - 10.12.2017
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer
Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer At six

Pharmacology - Health - 07.12.2017
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer
Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer First Phase III combination trial of a cancer immunotherapy to show improvement in progression-free survival as an initial treatment in advanced non-squamous non-small-cell lung cancer (NSCLC) Roche today announced results from the positi

Health - Pharmacology - 06.12.2017
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to
Novartis Kisqali is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to..

Health - Pharmacology - 06.12.2017

Health - Pharmacology - 06.12.2017
Personalized Health: National Funding for Basel-led Research Groups
Personalized Health: National Funding for Basel-led Research Groups
Nine research projects involving Basel-based researchers in the field of personalized health are to receive funding from the Swiss government: support will be given to researchers from the University

Health - Pharmacology - 05.12.2017
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data.

Health - Pharmacology - 30.11.2017
Novartis’ Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients
Novartis' Cosentyx is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients Unique Cosentyx (secukinumab) data reinforce treatment option for up to 90% of psoriasis patients who may develop nail or palmoplantar psoriasis - Cosentyx results represent the first data on biologic use for up to 2.5 years in these hard-to-treat types of psoriasis , Results add to body of e

Health - Pharmacology - 29.11.2017
UAE Ministry working with Birmingham on ’Happiness’ Project
Scientists from the University of Birmingham are uniting to support World Antibiotic Awareness Week (WAAW) from November 13th to 19th. The face of the University's ‘Old Joe' clock tower will be lit blue to mark the awareness week, which is led by the World Health Organization and aims to encourage people to seek advice from a qualified healthcare professional before taking antibiotics.

Pharmacology - Health - 29.11.2017
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention Patients with episodic migraine taking erenumab reported

Health - Pharmacology - 27.11.2017
Novartis’ Ultibro Breezhaler significantly improved COPD patients’ lung function after direct switch from Seretide
† New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide * †to Ultibro †Breezhaler †improved lung function and was well tolerated. † The FLASH study is the first randomized controlled trial to investigate the direct switch of patients from steroid-containing Seretide to the dual bronchodilator Ultibro†Breezhaler.

Psychology - Pharmacology - 27.11.2017
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Self-Help Book Works to Combat Burnout and Stress - Without a Therapist
Around a third of all employees find their work stressful. Interventions for stress and burnout are available, but often not accessible for many employees. A self-help book based on Acceptance and Commitment Therapy (ACT) has the potential to reduce burnout, stress and symptoms of depression - without any therapist contact.

Health - Pharmacology - 24.11.2017
Experimental drug trial seeks to improve treatment for head and neck cancer
A group of University of Birmingham research scientists has received a prestigious Innovators Award from US-based Kenneth Rainin Foundation to fund foundational research in Inflammatory Bowel Disease (IBD).

Pharmacology - Health - 22.11.2017
Birmingham joins new £5m UK Hardware Security Institute
A study by the University of Birmingham has found that statins are not always prescribed to patients who will benefit the most from them. This research by the team from the Institute of Applied Health Research examined the clinical records of 1.4 million patients who did not have existing cardiovascular disease and who were not taking, or had not been offered, statins in the past.

Health - Pharmacology - 15.11.2017
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000 deaths

Health - Pharmacology - 14.11.2017

Pharmacology - Health - 14.11.2017
New data reinforces clinical basis for switching to Sandoz biosimilar medicines
Sandoz strengthens position as global leader in biosimilars with new immunology data from four clinical studies for proposed biosimilars adalimumab and rituximab Efficacy and safety of biosimilar adalimumab and safety of biosimilar rituximab match reference medicines in multiple-switching and retreatment study respectively† Sandoz biosimilar adalimumab is under EMA review, while EC-approved Sandoz biosimilar rituximab is under review by the FDA

Pharmacology - Health - 14.11.2017
Novartis presents new data at SABCS across broad range of breast cancer patient populations, combination treatments and lines of therapy
Presentation of results from the Kisqali (ribociclib) MONALEESA-7 Phase III trial exclusively studying premenopausal women with HR+/HER2- advanced breast cancer† New MONALEESA-2 analyses focused on q

Health - Pharmacology - 13.11.2017
Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants
Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association Scientific Sessions 2017   The analysis showed a 31% reduction in cardiovascular death and a 31% reduction in all-cause mortality in patients whose inflammation - as measured by hsCRP - decreased below 2mg/L three months after initiating canakinumab

Health - Pharmacology - 13.11.2017
Novartis highlights its differentiated late stage pipeline at the R&D update and investor event
RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD   AMG 334 has a robust data package, even in difficult to treat patients, and is on track to be the first CGRP to market for treatment of patients with chronic or episodic migraine   Cosentyx has strong differentiation based on its unique biology, which has been proven to

Health - Pharmacology - 12.11.2017
New Novartis Entresto real world evidence data shows beneficial impact on quality of life in people living with heart failure
Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common physical activity such as exercise and other daily activities at 90 and 180 days after treatment initiation in a retrospective database study in patients with heart failure with reduced ejection fraction (HFrEF) in Germany Entresto significantly reduced levels of NT-proBNP, a key bl

Health - Pharmacology - 11.11.2017
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make m
« Previous 1 ... 8 9 10 11 12 13 14 15 16 ... 31 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |